These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2023873)

  • 1. Computer-aided dosage form design. III. Feasibility assessment for an oral prolonged-release phenytoin product.
    Irvin JR; Notari RE
    Pharm Res; 1991 Feb; 8(2):232-7. PubMed ID: 2023873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma concentrations as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: consequences for phenytoin therapy.
    Sawchuk RJ; Rector TS
    J Pharmacokinet Biopharm; 1979 Dec; 7(6):543-55. PubMed ID: 529023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and slow release phenytoin in epileptic patients at steady state: assessment of relative bioavailability utilizing Michaelis-Menten parameters.
    Sawchuk RJ; Pepin SM; Leppik IE; Gumnit RJ
    J Pharmacokinet Biopharm; 1982 Aug; 10(4):383-91. PubMed ID: 7153871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study.
    Rojanasthien N; Chaichana N; Teekachunhatean S; Kumsorn B; Sangdee C; Chankrachang S
    J Med Assoc Thai; 2007 Sep; 90(9):1883-93. PubMed ID: 17957935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualizing phenytoin dosage regimens using a programmable calculator.
    Ng PK
    Am J Hosp Pharm; 1980 Apr; 37(4):529-33. PubMed ID: 7377216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of a simplified method to determine bioavailability of an oral dose of phenytoin.
    Davis AL; Begg EJ; Kennedy MC; Graham GG
    J Pharmacokinet Biopharm; 1993 Apr; 21(2):195-208. PubMed ID: 8229680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained release of phenytoin following the oral administration of phenytoin sodium/ethylcellulose microcapsules in human subjects and rabbits.
    Karakasa I; Yagi N; Shibata M; Kenmotsu H; Sekikawa H; Takada M
    Biol Pharm Bull; 1994 Mar; 17(3):432-6. PubMed ID: 8019511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effectiveness of two oral phenytoin products and chronopharmacokinetics of phenytoin.
    Petker MA; Morton DJ
    J Clin Pharm Ther; 1993 Jun; 18(3):213-7. PubMed ID: 8345007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption characteristics of three phenytoin sodium products after administration of oral loading doses.
    Goff DA; Spunt AL; Jung D; Bellur SN; Fischer JH
    Clin Pharm; 1984; 3(6):634-8. PubMed ID: 6509876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dose on phenytoin absorption.
    Jung D; Powell JR; Walson P; Perrier D
    Clin Pharmacol Ther; 1980 Oct; 28(4):479-85. PubMed ID: 7408408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An efficient method for computer-aided dosage form design.
    Lam CF; Jiang Q; Notari RE
    Comput Biol Med; 1993 Nov; 23(6):475-82. PubMed ID: 8306626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer-aided dosage form design. I. Methods for defining a long-acting first-order delivery system of maximum formulating flexibility.
    Lee TY; Notari RE
    Pharm Res; 1987 Aug; 4(4):311-6. PubMed ID: 3508537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenytoin dosage individualization--five methods compared in the elderly.
    Hudson SA; Farquhar DL; Thompson D; Smith RG
    J Clin Pharm Ther; 1990 Feb; 15(1):25-34. PubMed ID: 2318914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison on bioequivalence of four phenytoin preparations in patients with multiple-dose treatment.
    Tsai JJ; Lai ML; Yang YH; Huang JD
    J Clin Pharmacol; 1992 Mar; 32(3):272-6. PubMed ID: 1564132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenytoin age-dose-concentration relationship in children.
    Suzuki Y; Mimaki T; Cox S; Koepke J; Hayes J; Walson PD
    Ther Drug Monit; 1994 Apr; 16(2):145-50. PubMed ID: 8009561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between microcrystalline and conventional phenytoin preparations: relative bioavailability and steady-state plasma concentrations.
    Boréus LO; Nergårdh A; Ehrnebo M; Theorell K
    J Neurol; 1980; 223(4):241-9. PubMed ID: 6157786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenytoin cumulation kinetics.
    Allen JP; Ludden TM; Burrow SR; Clementi WA; Stavchansky SA
    Clin Pharmacol Ther; 1979 Oct; 26(4):445-8. PubMed ID: 487692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenytoin dosage requirements and pharmacokinetic variables.
    Taylor JW; Murphy MJ; Berg MJ; Perry PJ; Lyon LW; Ludden TM
    Clin Pharm; 1983; 2(3):253-7. PubMed ID: 6883953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time for phenytoin concentration to peak: consequences of first-order and zero-order absorption.
    McCauley DL; Tozer TN; Winter ME
    Ther Drug Monit; 1989 Sep; 11(5):540-2. PubMed ID: 2815228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenytoin pharmacokinetic analysis and steady-state level prediction using a programmable calculator.
    Ng PK
    Int J Biomed Comput; 1980 Jul; 11(4):329-034. PubMed ID: 7399737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.